NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price, News & Analysis

$0.67
-0.01 (-1.48 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$0.65
Now: $0.6678
$0.69
50-Day Range N/A
52-Week Range
$0.37
Now: $0.6678
$1.50
Volume265,157 shs
Average Volume916,915 shs
Market Capitalization$108.46 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:MTNB
CUSIPN/A
CIKN/A
Phone+1-908-4431860

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees15
Market Cap$108.46 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.


Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced its earnings results on Tuesday, August, 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The firm earned $0.09 million during the quarter, compared to analysts' expectations of $0.06 million. View Matinas BioPharma's Earnings History.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Matinas BioPharma.

What price target have analysts set for MTNB?

4 analysts have issued 12 month price objectives for Matinas BioPharma's shares. Their predictions range from $4.00 to $5.00. On average, they anticipate Matinas BioPharma's share price to reach $4.6875 in the next twelve months. This suggests a possible upside of 601.9% from the stock's current price. View Analyst Price Targets for Matinas BioPharma.

What is the consensus analysts' recommendation for Matinas BioPharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Matinas BioPharma.

What are Wall Street analysts saying about Matinas BioPharma stock?

Here are some recent quotes from research analysts about Matinas BioPharma stock:
  • 1. HC Wainwright analysts commented, "Our price target of $4/share is based on an equally weighted composite of: (a) $2.47/share, as a 35x multiple of taxed and diluted 2033 EPS of $0.67 discounted back to 2019 at 18%; and (b) an NPV discounted cash flow between 2019-2033 of $4.81/share, with a discount rate of 12% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/14/2019)
  • 2. According to Zacks Investment Research, "Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia. " (7/17/2019)
  • 3. Maxim Group analysts commented, "Matinas reported 1Q19 with a net loss of ($4.3M) and cash of $39.4M. This included a $32.4M financing completed in March, which should provide funding into 2021." (5/16/2019)

Has Matinas BioPharma been receiving favorable news coverage?

News headlines about MTNB stock have trended positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Matinas BioPharma earned a news impact score of 2.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Matinas BioPharma.

Who are some of Matinas BioPharma's key competitors?

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include Corbus Pharmaceuticals (CRBP), Vistagen Therapeutics (VTGN), Amarin (AMRN), Highpower International (HPJ), Synergy Pharmaceuticals (SGYP), Marinus Pharmaceuticals (MRNS), AK Steel (AKS), Advaxis (ADXS), Aphria (APHA) and Sorrento Therapeutics (SRNE).

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the folowing people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 45)
  • Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 72)
  • Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 49)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 52)
  • Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.50%), Victory Capital Management Inc. (1.14%), Granite Point Capital Management L.P. (1.05%), Stonepine Capital Management LLC (0.47%), BlackRock Inc. (0.44%) and Northern Trust Corp (0.17%). Company insiders that own Matinas BioPharma stock include Adam K Stern, Herbert J Conrad, James S Scibetta, Jerome D Jabbour, Patrick G Lepore and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.

Which institutional investors are selling Matinas BioPharma stock?

MTNB stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Granite Point Capital Management L.P., Susquehanna International Group LLP and Victory Capital Management Inc.. View Insider Buying and Selling for Matinas BioPharma.

Which institutional investors are buying Matinas BioPharma stock?

MTNB stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Staley Capital Advisers Inc., Bank of New York Mellon Corp, Wells Fargo & Company MN, Northern Trust Corp and BlackRock Inc.. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, Herbert J Conrad, James S Scibetta, Jerome D Jabbour, Patrick G Lepore and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.6678.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $108.46 million. Matinas BioPharma employs 15 workers across the globe.View Additional Information About Matinas BioPharma.

What is Matinas BioPharma's official website?

The official website for Matinas BioPharma is http://www.matinasbiopharma.com/.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.


MarketBeat Community Rating for Matinas BioPharma (NYSEAMERICAN MTNB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  437
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel